MX338436B - Preparacion liofilizada de toxinas de botulismo. - Google Patents

Preparacion liofilizada de toxinas de botulismo.

Info

Publication number
MX338436B
MX338436B MX2013011119A MX2013011119A MX338436B MX 338436 B MX338436 B MX 338436B MX 2013011119 A MX2013011119 A MX 2013011119A MX 2013011119 A MX2013011119 A MX 2013011119A MX 338436 B MX338436 B MX 338436B
Authority
MX
Mexico
Prior art keywords
botulinum toxin
lyophilized preparation
present
transportation
animal
Prior art date
Application number
MX2013011119A
Other languages
English (en)
Other versions
MX2013011119A (es
Inventor
Hyun Ho Jung
Gi-Hyeok Yang
Chang Hoon Rhee
Hack Woo Kim
Sung Bum Kim
Seung Hwan Baek
Original Assignee
Medy Tox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47282510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX338436(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medy Tox Inc filed Critical Medy Tox Inc
Publication of MX2013011119A publication Critical patent/MX2013011119A/es
Publication of MX338436B publication Critical patent/MX338436B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un preparado farmacéutico liofilizado que contiene: -toxina botulínica, polisorbato y metionina; y -uno o más componentes seleccionados del grupo de los azucares, de los alcoholes de azúcar y de los compuestos jónicos, donde el preparado está libre de albúmina. El preparado farmacéutico liofilizado en donde la toxina botulínica se selecciona del grupo formado por Serotipos de Toxina A, B, C, D, E, F, y G.
MX2013011119A 2011-03-31 2012-03-30 Preparacion liofilizada de toxinas de botulismo. MX338436B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20110029577 2011-03-31
PCT/KR2012/002418 WO2012134240A2 (ko) 2011-03-31 2012-03-30 보툴리눔 독소의 동결건조제제
KR1020120033374A KR101395064B1 (ko) 2011-03-31 2012-03-30 보톨리눔 독소의 동결건조제제

Publications (2)

Publication Number Publication Date
MX2013011119A MX2013011119A (es) 2014-02-27
MX338436B true MX338436B (es) 2016-04-18

Family

ID=47282510

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013011119A MX338436B (es) 2011-03-31 2012-03-30 Preparacion liofilizada de toxinas de botulismo.
MX2016004606A MX355771B (es) 2011-03-31 2012-03-30 Preparacion liofilizada de toxinas de botulismo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016004606A MX355771B (es) 2011-03-31 2012-03-30 Preparacion liofilizada de toxinas de botulismo.

Country Status (22)

Country Link
US (3) US8920795B2 (es)
EP (3) EP3241547B1 (es)
JP (3) JP5826914B2 (es)
KR (1) KR101395064B1 (es)
CN (2) CN103596580A (es)
AU (2) AU2012233845B2 (es)
BR (1) BR112013025256B1 (es)
CA (1) CA2831908C (es)
CO (1) CO6821888A2 (es)
DK (2) DK2692350T4 (es)
ES (2) ES2810098T3 (es)
HK (1) HK1246174A1 (es)
HU (1) HUE050037T2 (es)
IL (1) IL228607B (es)
MX (2) MX338436B (es)
PL (2) PL2692350T5 (es)
PT (1) PT3241547T (es)
RU (2) RU2640922C1 (es)
SG (3) SG194039A1 (es)
SI (1) SI3241547T1 (es)
WO (1) WO2012134240A2 (es)
ZA (1) ZA201308115B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100852822B1 (ko) * 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
JP5259710B2 (ja) * 2007-07-10 2013-08-07 メディ‐トックス、インク． ボツリヌス毒素の安定性が改善された薬学的液状組成物
DK3332805T3 (da) 2008-12-31 2022-05-16 Revance Therapeutics Inc Injicerbare botulinumtoksinformuleringer
BRPI1015938A2 (pt) * 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
EP3241547B1 (en) * 2011-03-31 2020-05-20 Medy-Tox Inc. Lyophilized preparation of botulinum toxin
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
DK3188706T3 (da) 2014-09-02 2020-01-20 American Silver Llc Botulinumtoksin og kolloide sølvpartikler
EP3207936B1 (en) * 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
KR101737387B1 (ko) 2015-06-01 2017-05-18 유용우 2차 발효 홍삼을 이용한 건강기능식품의 제조방법
SG11201805195YA (en) * 2016-03-02 2018-07-30 Merz Pharma Gmbh & Co Kgaa Composition comprising botulinum toxin
KR20240023684A (ko) 2016-09-13 2024-02-22 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
CN107540732B (zh) * 2017-08-31 2020-07-14 青海省畜牧兽医科学院 一种d型肉毒毒素的仿生矿化加工方法及应用
KR101968873B1 (ko) * 2018-09-21 2019-04-29 아이큐어 주식회사 세포 침투 효과가 우수한 보툴리늄 유래 펩타이드를 포함하는 화장료 조성물
KR102259423B1 (ko) * 2018-11-30 2021-06-02 주식회사 휴온스바이오파마 보툴리눔 독소의 안정화 액상 조성물
WO2020111852A1 (ko) * 2018-11-30 2020-06-04 주식회사 휴온스글로벌 보툴리눔 독소의 안정화 액상 조성물
EP3927355A1 (en) 2019-02-21 2021-12-29 Merz Pharma GmbH & Co. KGaA Novel uses of botulinum neurotoxin for the treatment of tremor
CN110637814B (zh) * 2019-10-22 2021-11-19 青海省畜牧兽医科学院 一种d型肉毒毒素的微囊化制备方法
WO2021086123A1 (ko) * 2019-10-31 2021-05-06 휴젤㈜ 보툴리눔 독소에 대한 마이크로 구조체 제형화 기술
EP4186520A4 (en) 2020-07-23 2024-05-01 Medytox Inc. THERAPEUTIC AGENT AGAINST CANCER
KR102414997B1 (ko) * 2020-09-29 2022-06-29 주식회사 엘지생활건강 안정성이 개선된 재조합 보툴리눔 독소 경쇄 단백질 조성물
KR20220114183A (ko) * 2021-02-08 2022-08-17 주식회사 대웅 장기 저장이 가능한 보툴리눔 독소 동결건조 제형 조성물
KR20230001260A (ko) 2021-06-28 2023-01-04 (주)메디톡스 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법
KR20230001254A (ko) 2021-06-28 2023-01-04 (주)메디톡스 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법
KR102427362B1 (ko) 2021-11-11 2022-08-01 (주)이니바이오 보툴리눔 독소 제제의 건조 공정
CA3238234A1 (en) * 2021-11-15 2023-05-19 Medytox Inc. Botulinum neurotoxin composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
PT1398038E (pt) * 2000-02-08 2007-02-28 Allergan Inc Composições farmacêuticas de toxina botulínica
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
CN101175478A (zh) * 2005-10-06 2008-05-07 阿勒根公司 非蛋白稳定的梭菌毒素药物组合物
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
MX2009012570A (es) * 2007-06-01 2010-03-15 Merz Pharma Gmbh & Co Kgaa Proceso para proveer un relajante muscular estable a la temperatura a base del componente neurotoxico de la toxina botulinica en forma solida.
JP5259710B2 (ja) * 2007-07-10 2013-08-07 メディ‐トックス、インク． ボツリヌス毒素の安定性が改善された薬学的液状組成物
CN105833254A (zh) * 2008-12-10 2016-08-10 阿勒根公司 梭菌毒素药物组合物
KR101135449B1 (ko) * 2009-03-10 2012-04-13 한국과학기술연구원 헤파라나제 활성 측정용 이온 복합체 나노 입자 및 그 제조방법
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP3241547B1 (en) * 2011-03-31 2020-05-20 Medy-Tox Inc. Lyophilized preparation of botulinum toxin
US20130236446A1 (en) * 2012-03-12 2013-09-12 William J. Binder Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the mouth

Also Published As

Publication number Publication date
SG10201605324PA (en) 2016-08-30
JP2014509644A (ja) 2014-04-21
US9198958B2 (en) 2015-12-01
US20150064166A1 (en) 2015-03-05
PL2692350T3 (pl) 2017-10-31
EP2692350A2 (en) 2014-02-05
RU2013148119A (ru) 2015-05-27
HK1246174A1 (zh) 2018-09-07
JP2016199599A (ja) 2016-12-01
EP2692350A4 (en) 2014-12-10
ES2810098T3 (es) 2021-03-08
WO2012134240A2 (ko) 2012-10-04
ES2636680T5 (es) 2023-10-31
ZA201308115B (en) 2014-07-30
JP5826914B2 (ja) 2015-12-02
IL228607A0 (en) 2013-12-31
MX355771B (es) 2018-04-30
EP3241547A1 (en) 2017-11-08
AU2012233845B2 (en) 2015-11-19
CN103596580A (zh) 2014-02-19
EP2692350B1 (en) 2017-05-03
AU2016201040A1 (en) 2016-03-10
PL3241547T3 (pl) 2021-02-08
DK2692350T3 (en) 2017-08-21
KR101395064B1 (ko) 2014-05-19
EP2692350B2 (en) 2023-06-28
CO6821888A2 (es) 2013-12-31
CA2831908C (en) 2018-11-13
SG10202013124XA (en) 2021-02-25
CN109925284A (zh) 2019-06-25
AU2012233845A1 (en) 2013-10-31
WO2012134240A3 (ko) 2013-01-03
EP3756656A1 (en) 2020-12-30
IL228607B (en) 2018-10-31
JP2016020382A (ja) 2016-02-04
PT3241547T (pt) 2020-08-26
KR20120112248A (ko) 2012-10-11
RU2640922C1 (ru) 2018-01-12
JP6173547B2 (ja) 2017-08-02
HUE050037T2 (hu) 2020-11-30
DK2692350T4 (da) 2023-09-04
MX2013011119A (es) 2014-02-27
ES2636680T3 (es) 2017-10-06
BR112013025256B1 (pt) 2022-01-18
SG194039A1 (en) 2013-11-29
US8920795B2 (en) 2014-12-30
PL2692350T5 (pl) 2023-10-09
US20140086900A1 (en) 2014-03-27
JP6005239B2 (ja) 2016-10-12
SI3241547T1 (sl) 2020-10-30
EP3241547B1 (en) 2020-05-20
DK3241547T3 (da) 2020-08-17
US20160089442A1 (en) 2016-03-31
CA2831908A1 (en) 2012-10-04
AU2016201040B2 (en) 2017-05-25
RU2574011C2 (ru) 2016-01-27
BR112013025256A2 (pt) 2017-02-07

Similar Documents

Publication Publication Date Title
MX338436B (es) Preparacion liofilizada de toxinas de botulismo.
MX2017017157A (es) Composiciones de bebida lista para beber estables que comprende agentes activos lipofilos.
MX371497B (es) Composiciones y metodos que comprenden una variante de enzima lipolitica.
EP2802652A4 (en) CLOSTRIDIUM HISTOLYTICUM ENZYME AND METHOD FOR USE THEREOF
UY34328A (es) ?composiciones y métodos para controlar malezas comprendiendo un polinucleótido y agente de transferencia, y que modulan protoporfirinógeno ix oxidasa?.
MX340172B (es) Formulaciones estables de una enzima degradadora de hialuronano.
MX2015003874A (es) Modulacion de ire1.
UY34332A (es) Composiciones y métodos para controlar malezas co mprendiendo un polinucleótido y agente de transfe rencia, y que modulan la fitoeno desaturasa?.
WO2013154657A3 (en) Turbine blade damper seal
WO2013086024A3 (en) Dermal filler compositions
AU337887S (en) Allsaw
MX2014016121A (es) Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular.
MX355128B (es) Péptidos inhibidores de bace1 y uso de los mismos para el tratamiento de enfermedades o trastornos neurológicos.
GB2519697A (en) Golf fitting systems and related methods
EP2575452A4 (en) ANTIMICROBIAL COMPOSITIONS
PH12014502858A1 (en) Racecadotril lipid compositions
MX2017000437A (es) Ensamble de pesca de liberacion rapida.
MX350970B (es) Métodos y composiciones para extender la vida útil en depósito de productos de plantas.
PH12015501390A1 (en) Tablets with improved acceptance and good storage stability
UY33656A (es) Composición aceleradora para elastómeros
IN2014MN02257A (es)
EP2902480A4 (en) PAECILOMYCES VARIOTII VAR. BRUNNEOLUS GPP1101B AND PROCESS FOR PREPARING THE SAME
AU337888S (en) Allsaw
MX366768B (es) Tableta orodispersable de sildenafil y metodo para preparar la misma.
金鑫 The Big Bang Theory and the California Instiute of Technology

Legal Events

Date Code Title Description
FG Grant or registration